Anika Therapeutics (ANIK) Other Non-Current Liabilities (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Other Non-Current Liabilities data on file, last reported at $726000.0 in Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities fell 2.42% year-over-year to $726000.0 in Q1 2026; TTM through Mar 2026 was $726000.0, a 2.42% decrease from a year earlier, with the FY2025 full-year figure at $701000.0, down 9.2% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $726000.0, up from $701000.0 in the prior quarter.
• Over the last five years, Other Non-Current Liabilities for ANIK reached as high as $806000.0 in Q3 2024 and fell as low as $398000.0 in Q4 2022.
• Historically, Other Non-Current Liabilities has averaged $577882.4 across 5 years, with a median of $587000.0 in 2022.
• Across the five-year window, Other Non-Current Liabilities plunged 96.53% in 2022 and surged 101.5% in 2024, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $398000.0 in 2022, then grew by 1.51% to $404000.0 in 2023, then jumped by 91.09% to $772000.0 in 2024, then declined by 9.2% to $701000.0 in 2025, then increased by 3.57% to $726000.0 in 2026.
• Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $726000.0 in Q1 2026, $701000.0 in Q4 2025, and $761000.0 in Q3 2025.